24/7 Market News Snapshot 16 July, 2025 – Intelligent Bio Solutions Inc. Common Stock (NASDAQ:INBS)

July 16, 2025

DENVER, Colo., 16 July, 2025 (www.247marketnews.com) – (Nasdaq:INBS) are discussed in this article.
Intelligent Bio Solutions Inc. (Nasdaq:INBS) has experienced significant momentum in the market, opening at $2.09 and currently trading at $2.115, reflecting a remarkable gain of 11.32%. This upward movement follows a closing price of $1.90 in the previous session, indicating a strong bullish sentiment among investors. The current trading volume of 647.42K suggests robust interest in the stock, signaling potential continued upward momentum. With technical indicators hinting at forming support levels, the increase in volume aligns well with the price gain, reinforcing the trend. Investors are advised to pay attention to key resistance levels as INBS continues its upward trajectory.

Additionally, Intelligent Bio Solutions has made strides in expanding its global reach by entering into a significant distribution agreement with SMARTOX®, a reputable provider of drug and alcohol screening services. This partnership aims to broaden the availability of the innovative SmarTest Patch drug detection product to international markets beyond the confines of the United States and Canada. The collaboration builds upon an existing relationship, as SMARTOX serves as the U.S. distributor for INBS’s Intelligent Fingerprinting Drug Testing Solution in specific forensic contexts.

Harry Simeonidis, President and CEO of Intelligent Bio Solutions, highlighted the importance of this agreement, stating that it allows for the introduction of complementary technology tailored to meet diverse customer needs across various sectors, including justice, rehabilitation, and workplace environments. With the inclusion of the SmarTest Patch, the Company’s product portfolio is set to strengthen its competitive position in a global drug testing market projected to reach approximately $18.6 billion by 2030. Moreover, the Company is also pursuing regulatory approvals for its fingerprint sweat-based drug testing technology in the United States, positioning itself to further capitalize on the increasing demand for innovative drug screening solutions worldwide.

Related news for (INBS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.